<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05036018</url>
  </required_header>
  <id_info>
    <org_study_id>2021-0165</org_study_id>
    <nct_id>NCT05036018</nct_id>
  </id_info>
  <brief_title>RanDOmized stUdy Comparing Both Latest Generation Self-Expanding Valves and loCal anestHesia vs. cOnscIous Sedation in transCathEter Aortic Valve Implantation</brief_title>
  <acronym>DOUBLE-CHOICE</acronym>
  <official_title>RanDOmized stUdy Comparing Both Latest Generation Self-Expanding Valves and loCal anestHesia vs. cOnscIous Sedation in transCathEter Aortic Valve Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leipzig Heart Science gGmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Heart Center Leipzig - University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Leipzig Heart Science gGmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-label, 2 x 2 factorial, prospective, randomized, national, multicenter study to compare&#xD;
      latest-generation self-expanding valves and isolated local anesthesia versus local anesthesia&#xD;
      with conscious sedation in transcatheter aortic valve implantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the DOUBEL-CHOICE study is to demonstrate non-inferiority of a&#xD;
      latest-generation self-expanding valve (SEV) (ACURATE neo2, Boston Scientific, Marlborough,&#xD;
      MA, USA) in comparison to another latest-generation SEV (Evolut Pro and Pro+, Medtronic Inc.,&#xD;
      Minneapolis, MN, USA) and isolated local anesthesia in comparison with local anesthesia and&#xD;
      conscious sedation with respect to safety and efficacy in patients with severe symptomatic&#xD;
      aortic stenosis undergoing transfemoral TAVI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 30, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2032</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>Patients will be randomized to one of four treatment groups in a 1:1:1:1 ratio</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Blinding of cardiologists, anesthesiologists and patients is not possible due to the type of interventions.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>composite of all-cause mortality, stroke, moderate or severe prosthetic valve regurgitation, and permanent pacemaker implantation at 30-day follow-up</measure>
    <time_frame>Day 30</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>a composite of all-cause mortality and occurrence of acute delirium assessed according to the Confusion Assessment Method for Intensive Care Units (CAM-ICU) criteria at 30-day follow-up</measure>
    <time_frame>Day 30</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">836</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients treated with the ACURATE neo2 valve under isolated local anesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients treated with the ACURATE neo2 valve under local anesthesia with conscious sedation (CS)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients treated with the Evolut Pro or Pro+ valve under isolated local anesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients treated with the Evolut Pro or Pro+ valve under local anesthesia with conscious sedation (CS)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ACURATE neo2</intervention_name>
    <description>The ACURATE neo2 valve will be implanted using a two-step mechanism during transfemoral transcatheter aortic valve implantation (TAVI). Balloon predilatation will be recommended in the ACURATE neo 2 valve group.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Isolated local anesthesia</intervention_name>
    <description>Local anesthesia will be performed by injecting Lidocaine into the skin, subcutis, and around the femoral artery.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CoreValve Evolut Pro and Pro+</intervention_name>
    <description>The Evolut Pro or Pro+ valve is positioned in a controlled manner either without pacing or under 'slow-rapid' pacing with allowance for limited repositioning and is anchored to the annulus and ascending aorta.</description>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>local anesthesia with conscious sedation</intervention_name>
    <description>For conscious sedation remifentanil, Propofol and dexmedetomidine (alone or in combination) are allowed within a local/institutional standard operating procedure using EEG monitoring. Continuous CO2-monitoring via face mask should be established during sedation and all patients will receive supplemental oxygen by face mask. Local anesthesia will be performed by injecting Lidocaine into the skin, subcutis, and around the femoral artery.</description>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Severe symptomatic aortic valve stenosis (AVA ≤1 cm² or 0.6 cm²/m²) with indication&#xD;
             for transcatheter aortic valve implantation according to heart team consensus&#xD;
&#xD;
          -  Perimeter-derived native aortic valve annulus diameter measuring 21-27 mm&#xD;
&#xD;
          -  Heart team consensus that the patient is anatomically suitable for both device types&#xD;
&#xD;
          -  Suitability for transfemoral vascular access&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Life expectancy &lt;12 months due to comorbidities&#xD;
&#xD;
          -  Native aortic valve annulus &lt;21 mm and &gt;27 mm&#xD;
&#xD;
          -  Bicuspid aortic valve&#xD;
&#xD;
          -  Cardiogenic shock or hemodynamic instability&#xD;
&#xD;
          -  Active endocarditis&#xD;
&#xD;
          -  Contraindications for transfemoral access&#xD;
&#xD;
          -  Active peptic ulcer or upper gastro-intestinal bleeding &lt;2 weeks&#xD;
&#xD;
          -  Hypersensitivity or contraindication to aspirin, heparin or clopidogrel&#xD;
&#xD;
          -  Contraindication for a specific mode of anesthesia as judged by the cardiac anesthesia&#xD;
             representative of the Heart Team&#xD;
&#xD;
          -  Clear patient-specific clinical or anatomic reasons to prefer one form of anesthesia&#xD;
             or valve type over the other&#xD;
&#xD;
          -  Active infection requiring antibiotic treatment&#xD;
&#xD;
          -  Age &lt;18 years&#xD;
&#xD;
          -  Participation in another trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Holger Thiele, Prof. Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Heart Center Leipzig at University of Leipzig, Department of Internal Medicine/Cardiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Holger Thiele, Prof. Dr.</last_name>
    <phone>+49341865</phone>
    <phone_ext>1428</phone_ext>
    <email>holger.thiele@medizin.uni-leipzig.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mohamed Abdel-Wahab, Prof. Dr.</last_name>
    <phone>+49341865</phone>
    <phone_ext>1427</phone_ext>
    <email>mohamed.abdel-wahab@medizin.uni-leipzig.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Heart Center Leipzig at University of Leipzig, Department of Internal Medicine/Cardiology</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holger Thiele, Prof. Dr.</last_name>
      <phone>+49341865</phone>
      <phone_ext>1428</phone_ext>
      <email>holger.thiele@medizin.uni-leipzig.de</email>
    </contact>
    <contact_backup>
      <last_name>Mohamed Abdel-Wahab, Prof. Dr.</last_name>
      <phone>+49341865</phone>
      <phone_ext>1427</phone_ext>
      <email>mohamed.abdel-wahab@medizin.uni-leipzig.de</email>
    </contact_backup>
    <investigator>
      <last_name>Hans-Josef Feistritzer, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 30, 2021</study_first_submitted>
  <study_first_submitted_qc>August 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2021</study_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TAVI</keyword>
  <keyword>ACURATE neo2</keyword>
  <keyword>Evolut Pro</keyword>
  <keyword>local anesthesia</keyword>
  <keyword>conscious sedation</keyword>
  <keyword>monitored anesthesia care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

